If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
2,001.00    -3.00 (-0.15%)
Bid:
2,001.00
Ask:
2,002.00
Spread: 1.00 (0.05%)
Market Cap: £80.15b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

15 May 2023 15:30

RNS Number : 4636Z
GSK PLC
15 May 2023
 

GSK plc (the 'Company')

Vesting of 2020 Performance Share Plan Top-Up Award

This notification sets out the vesting details of a "top-up" conditional share award made to the Chief Executive Officer (CEO) on 6 May 2020 under the GSK 2017 Performance Share Plan ('PSP'), following the approval of the 2020 Remuneration Policy at the AGM that year.

This "top-up" PSP award, equivalent to 25% of the CEO's base salary, was made to deliver in aggregate for 2020 an award level of 575% of base salary, increasing her award level from 550%. It was subject to the same business performance conditions as the main 2020 award, with a three-year performance period from 1 January 2020 to 31 December 2022. The main 2020 award vesting was announced on 14 February 2023. The "top-up" award has now vested on the same basis ie 52% vesting 48% lapsed, following the third anniversary of the grant. The vested shares are subject to a further two-year vesting period.

This notification that follows is for the "top-up" award made to the CEO and details the PSP conditional award that vested, including dividends accrued, on 9 May 2023. The balance of the award has lapsed.

The closing price of Ordinary Shares of GSK plc on the vesting date was £14.462.

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The number of Ordinary Shares vesting on the "top-up" award granted in 2020 under the Company's 2017 Performance Share Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,729

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2023-05-09

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFUFLIEDSESI
Date   Source Headline
11th Aug 20257:00 amRNSFDA to review gonorrhea indication for gepotidacin
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSCureVac/BioNTech mRNA patent litigation settlement
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20257:00 amRNSTransaction in Own Shares
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20253:00 pmRNSTotal Voting Rights
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
30th Jul 20257:05 amRNSTransaction in Own Shares
30th Jul 20257:00 amRNS2nd Quarter Results
29th Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:00 amRNSGSK enters Hengrui Pharma collaboration agreements
28th Jul 20257:00 amRNSTransaction in Own Shares
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20255:00 pmRNSBlenrep approved in the EU for multiple myeloma
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20255:00 pmRNSUS FDA review extended for Blenrep
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20253:30 pmRNSDirector/PDMR Shareholding
18th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSBlenrep US ODAC outcome
17th Jul 20257:00 amRNSGSK’s Shingrix Fully Liquid FDA approval
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20253:30 pmRNSDirector/PDMR Shareholding
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20253:30 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSGSK submits Arexvy for adults 18-49 AIR to FDA
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20254:00 pmRNSGSK completes acquisition of efimosfermin for SLD
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20253:00 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSTransaction in Own Shares
30th Jun 20257:00 amRNSTransaction in Own Shares
27th Jun 20257:00 amRNSTransaction in Own Shares
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20253:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.